Signaling Pathway News and Research

RSS

Nanoparticle delivers antisense agent to tumors

A multifunctional drug delivery system consisting of a lipid-based nanoparticle, a standard anticancer drug, and a short nucleic acid designed to augment the activity of that drug has demonstrated the ability to treat drug-resistant tumor cells.

15 Jun 2008

You may not be what you eat after all!

A new study shows that increased eating does not necessarily lead to increased fat. The finding in the much-studied roundworm opens the possibility of identifying new targets for drugs to control weight, the researchers say.

3 Jun 2008

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

2 Jun 2008

Most comprehensive kinome collection

Scientists from University of Helsinki, Institute of Molecular Medicine in Finland and OriGene Technologies joined effort in creating the most comprehensive kinome collection of nearly all predicted human protein kinases, including the functional kinases and their kinase-deficient counterparts. Equipped with this collection, the authors successfully identified novel kinase regulators in Hedgehog signaling pathway and in activation of Karposi's Sarcoma herpesvirus.

5 May 2008

Analysis of alcoholics' brains suggests treatment target

An analysis of brain tissue samples from chronic alcoholics reveals changes that occur at the molecular level in alcohol abuse - and suggests a potential treatment target, according to researchers from Wake Forest University School of Medicine.

2 May 2008

Researchers report the cloning of a key group of human genes, the protein kinases

Although the human genome has been sequenced, research into mechanism of action of genes has been hampered by the fact that most human genes have not been isolated.

2 May 2008

New study raises questions about prostate cancer therapies targeting insulin-like growth factor receptor

Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results especially if a major tumor suppressor gene - p53 - is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.

1 May 2008

Small molecule nutlin-3a activates an important cancer suppressor gene

By activating a cancer suppressor gene, a small molecule called nutlin-3a can block cancer cell division, according to researchers at the National Cancer Institute (NCI), part of the National Institutes of Health.

1 May 2008

Study raises questions about prostate cancer therapies targeting IGF-1

1 May 2008

AMPK signaling helps explain how cell growth is inhibited when nutrients are low

A team of scientists at the Salk Institute for Biological Studies think they know how many-if not most-living organisms answer this question. They recently showed that when food supplies dwindle, mammals, fruitflies, or frogs probably activate the same ancient cell signaling pathway in order to conserve energy.

24 Apr 2008

Discovery of primary driver of tumor development in the stomach

In a discovery that could lead to the development of new treatments for gastric cancer, scientists at the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) have discovered what appears to be the primary driver of tumor development in the stomach.

22 Apr 2008

Fat-cell hormone linked to kidney disease

Reduced levels of a hormone produced by fat cells and linked to the development of insulin resistance may also be related to a higher risk of kidney disease, according to a study led by researchers at the University of California, San Diego School of Medicine and Thomas Jefferson University.

22 Apr 2008

Discovery of new way to prevent cardiac fibrosis

In a study that points to a new strategy for preventing or possibly reversing fibrosis - the scarring that can lead to organ and tissue damage - researchers at the University of California, San Diego School of Medicine have determined that a molecule called Epac (Exchange protein activated by cAMP1), plays a key role in integrating the body’s pro- and anti-fibrotic response.

22 Apr 2008

Theranostics Health to commercialize microdissection technology from NIH

Theranostics Health announced that it has received an exclusive license from the National Institutes of Health (NIH) to commercialize microdissection including Laser Capture Microdissection (LCM) combined with protein analysis for cancer diagnostics and companion diagnostics.

21 Apr 2008

Interaction networks: the new path to drug discovery

Although the pharmaceutical industry has dedicated enormous research efforts over the last 50 years to identify new targets and develop new active ingredients, these efforts have met with limited success.

17 Apr 2008

TOR signaling and dietary restriction

University of Washington scientists have uncovered details about the mechanisms through which dietary restriction slows the aging process.

17 Apr 2008

Lipitor and Celebrex combined may halt prostate cancer

Researchers at Rutgers' Ernest Mario School of Pharmacy have shown that administering a combination of the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) and Lipitor (atorvastatin, a cholesterol lowering drug) stops the transition of early prostate cancer to its more aggressive and potentially fatal stage.

15 Apr 2008

Brain study may lead to improved epilepsy treatments

Using a rodent model of epilepsy, researchers found one of the body's own neurotransmitters released during seizures, glutamate, turns on a signaling pathway in the brain that increases production of a protein that could reduce medication entry into the brain.

15 Apr 2008

Researchers study Rituximab's action on cancer stem cells

Preliminary data from one of the first clinical trials to test a stem cell-targeting drug in cancer patients shows that while the drug did not prolong survival, its suppressing effect on patients' stem cells was impressive enough to send investigators looking for a better drug to try.

13 Apr 2008

Developing cancer treatments directed at critical developmental pathway

Researchers from the University of Pennsylvania School of Medicine and colleagues discovered that the Notch signaling pathway, which determines the development of many cell types, and is also implicated in some cancers, is not universally essential for the maintenance of stem cells.

11 Apr 2008